NCT07315139

Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients

Effect of Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Ain Shams University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aimed to determine the impact of Pentoxifylline on inflammatory biomarkers and the progression of chronic kidney disease in non-diabetic patients.

Detailed description

Chronic kidney disease (CKD) is a progressive condition that affects \>10% of the general population worldwide, amounting to \>800 million individuals. The diagnosis of CKD is established by laboratory testing, most often by estimating glomerular filtration rate (GFR) from a filtration marker, such as serum creatinine or cystatin C, using various formulas, or by testing urine for albumin or protein (or both). Pentoxifylline (PTX), a synthetic dimethylxanthine derivative used initially to treat intermittent claudication in patients with peripheral arterial disease due to its hemorheological effects, has been shown to have potent antioxidant, anti-inflammatory, antidiabetic, anti-cellular-damage, and antifibrotic effects.

Conditions

• Pentoxifylline
• Inflammatory Markers
• Non-Diabetic
• Chronic Kidney Disease

Interventions

Type	Name	Description
DRUG	Angiotensin-converting enzyme inhibitors (Ramipril)	Patients received the standard therapy. The routine standard consisted of angiotensin-converting enzyme inhibitors (ACEI) (Ramipril 1.25 mg), a calcium-based phosphate binder (calcium acetate 700 mg, containing 180 mg of calcium), alfacalcidol (0.25 µg), antihypertensive medications, and diuretics.
DRUG	Pentoxifylline	Patients received one capsule of Pentoxifylline 400 mg twice daily for 6 months, in addition to their standard therapy.

Timeline

• Start date: 2023-02-01
• Primary completion: 2023-08-31
• Completion: 2023-08-31
• First posted: 2026-01-02
• Last updated: 2026-01-02

Locations

1 site across 1 country: Egypt